ReviewJournal of the American Heart Association2025
Regulatory Roles of Mitochondrial tRNA-Derived Fragments in Cardiovascular Health and Disease.
Review in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The dark genome in cardiovascular medicine.European heart journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial tRNA-derived RNA fragments (mt-tRFs) are small noncoding RNAs generated through specific cleavage. Once considered degradation products, mt-tRFs are now recognized as bioactive regulatory molecules with critical roles in physiological and pathological processes. Given the heart's exceptional mitochondrial density and energy dependence, mt-tRFs serve as important signaling mediators within the mitochondria-nucleus communication network, exhibiting significant potential in maintaining cardiovascular homeostasis and contributing to disease development. This review systematically examines mt-tRF biogenesis, classification, and functional mechanisms, emphasizing their roles in cardiac development and vascular homeostasis. We analyze mt-tRF involvement in major cardiovascular diseases, including mitochondrial cardiomyopathies, cardiac hypertrophy, heart failure, myocardial ischemia-reperfusion injury, hypertension, and pulmonary arterial hypertension, highlighting disease-specific expression profiles and functional consequences. The clinical potential of mt-tRFs as emerging biomarkers and therapeutic targets presents promising opportunities for cardiovascular medicine. Through comprehensive analysis of their regulatory mechanisms and disease associations, this review provides insights into cardiovascular pathogenesis and supports the development of novel diagnostic and therapeutic strategies, positioning mt-tRFs as valuable targets for precision cardiovascular medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.